Cereno Scientific initiates collaboration with the Pulmonary and Vascular Research Institute (PVRI)
Cereno Scientific (Nasdaq First North: CRNO B), a pioneering biotech developing innovative treatments for rare and common cardiovascular disease, with its lead program CS1 currently being evaluated in a Phase II clinical study in the rare disease Pulmonary Arterial Hypertension (PAH), today announced that the Company will join the PVRI Roundtable (Pulmonary and Vascular Research Institute). Cereno will, amongst other things, participate in PVRI’s Innovative Drug Development Initiative (IDDI), addressing the most challenging issues faced by pharma, researchers, regulators, and clinicians and